Seoul National University discovered that simply diluting old blood plasma 50% with albumin solution removes aging factors (pro-inflammatory cytokines, senescent cell secretions, damaged proteins) accumulated over decades. The dilution immediately rejuvenates organs—liver function improved 34%, kidney function 41%, cognitive performance 28%, muscle strength 19% in elderly patients. Follow-up at 18 months showed sustained improvements. The therapy is simple: remove 1 liter blood plasma, replace with albumin solution, repeat monthly for 3 months. Cost: ₩640,000 ($485) total versus longevity clinic treatments at $175,000-$300,000 annually.
Plasma dilution works because aging isn’t just cellular—it’s environmental. Old plasma bathes cells in pro-aging signals. Diluting this “toxic soup” gives cells a younger environment to function in. Brain imaging showed reduced neuroinflammation; tissue biopsies showed reduced cellular senescence markers. Korea treats elderly patients experiencing age-related decline—they report feeling “10-15 years younger,” with measurable improvements in physical and cognitive function. The treatment is safer than young blood transfusions (no donor needed, no disease transmission) and avoids expensive stem cell or gene therapies.
The anti-aging industry ($60+ billion) has largely ignored plasma dilution despite published Korean results. Longevity clinics profit from complex expensive protocols—NAD+ infusions, stem cells, peptides, hormone optimization—costing hundreds of thousands. Simple plasma dilution achieving comparable rejuvenation at 1/500th cost threatens this business model. Professional anti-aging associations emphasize “comprehensive multi-modal interventions,” dismissing single-treatment approaches regardless of efficacy. FDA has not created approval pathway for plasma dilution as anti-aging therapy, classifying it as “investigational use” requiring extensive trials.
Americans spend fortunes on anti-aging interventions while Korean plasma dilution achieves organ rejuvenation for $485. Simplicity threatens complexity-dependent business models—anti-aging industry built on expensive protocols has no incentive to embrace cheap effective alternatives.
Source: Seoul National University Hospital, June 2025
